22.01
2.56%
0.55
After Hours:
22.20
0.19
+0.86%
Schrodinger Inc stock is traded at $22.01, with a volume of 439.95K.
It is up +2.56% in the last 24 hours and up +24.49% over the past month.
Schrodinger Inc is a healthcare-based software company. Its operating segments are Software and Drug discovery. Through the Software segment, the company is focused on selling software to transform drug discovery across the life sciences industry and customers in materials science industries. In the Drug discovery segment, it is engaged in generating revenue from a portfolio of preclinical and clinical programs, internally and through collaborations. It generates revenue from the sales of software solutions and from research funding and milestone payments from its drug discovery collaborations.
See More
Previous Close:
$21.46
Open:
$21.64
24h Volume:
439.95K
Relative Volume:
0.65
Market Cap:
$1.58B
Revenue:
$188.48M
Net Income/Loss:
$-143.14M
P/E Ratio:
39.30
EPS:
0.56
Net Cash Flow:
$-158.83M
1W Performance:
+14.81%
1M Performance:
+24.49%
6M Performance:
+0.14%
1Y Performance:
-29.39%
Schrodinger Inc Stock (SDGR) Company Profile
Name
Schrodinger Inc
Sector
Industry
Phone
503-299-1150
Address
1540 BROADWAY, NEW YORK, NY
Compare SDGR with other stocks
Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
---|---|---|---|---|---|---|
SDGR
Schrodinger Inc
|
22.01 | 1.58B | 188.48M | -143.14M | -158.83M | 0.56 |
VEEV
Veeva Systems Inc
|
226.76 | 36.93B | 2.57B | 615.26M | 996.76M | 3.32 |
SOLV
Solventum Corp
|
72.48 | 12.43B | 8.26B | 66.00M | 1.17B | 0.00 |
TEM
Tempus Ai Inc
|
62.98 | 10.01B | 640.44M | -743.28M | -206.93M | 0.00 |
DOCS
Doximity Inc
|
53.39 | 9.94B | 493.63M | 160.55M | 162.20M | 0.55 |
HQY
Healthequity Inc
|
102.47 | 8.91B | 1.10B | 105.67M | -197.98M | 0.1475 |
Schrodinger Inc Stock (SDGR) Upgrades & Downgrades
Date | Action | Analyst | Rating Change |
---|---|---|---|
Jul-02-24 | Initiated | Leerink Partners | Outperform |
Dec-05-23 | Initiated | KeyBanc Capital Markets | Overweight |
May-05-23 | Resumed | Piper Sandler | Overweight |
Dec-19-22 | Initiated | Goldman | Neutral |
Mar-01-22 | Initiated | Citigroup | Buy |
Nov-19-21 | Downgrade | Morgan Stanley | Overweight → Equal-Weight |
Nov-19-21 | Initiated | Piper Sandler | Overweight |
Nov-11-21 | Downgrade | BofA Securities | Buy → Neutral |
Oct-13-21 | Initiated | Berenberg | Buy |
Sep-01-21 | Upgrade | Morgan Stanley | Equal-Weight → Overweight |
May-25-21 | Initiated | Craig Hallum | Buy |
Nov-23-20 | Upgrade | BofA Securities | Neutral → Buy |
Oct-12-20 | Upgrade | Jefferies | Hold → Buy |
Mar-02-20 | Initiated | BMO Capital Markets | Outperform |
Mar-02-20 | Initiated | Jefferies | Hold |
Mar-02-20 | Initiated | Morgan Stanley | Equal-Weight |
View All
Schrodinger Inc Stock (SDGR) Latest News
Rubric Capital Management LP Grows Position in Schrödinger, Inc. (NASDAQ:SDGR) - MarketBeat
Algert Global LLC Has $2.35 Million Position in Schrödinger, Inc. (NASDAQ:SDGR) - MarketBeat
Massachusetts Financial Services Co. MA Purchases 717,059 Shares of Schrödinger, Inc. (NASDAQ:SDGR) - MarketBeat
Schrodinger, Inc. (SDGR) Reports Q3 Loss, Misses Revenue Estimates - MSN
Detailed Analysis of Molecular Modeling for Drug Development - openPR
Quest Partners LLC Purchases 39,218 Shares of Schrödinger, Inc. (NASDAQ:SDGR) - MarketBeat
Schrödinger, Inc. (NASDAQ:SDGR) Receives Average Recommendation of "Moderate Buy" from Analysts - MarketBeat
Schrödinger: Positive Signs Despite The Share Price Decline (SDGR) - Seeking Alpha
Gates Foundation awards second predictive toxicology grant - Philanthropy News Digest
Schrödinger to Present at Piper Sandler 36th Annual Healthcare Conference - Business Wire
Schrödinger’s stock pops as it enters collaboration pact with Novartis worth up to $2.5 billion - MSN
Schrödinger, Novartis Ink Up-to-$2.3B Collaboration, Software Agreement - Genetic Engineering & Biotechnology News
Schrödinger Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)November 19, 2024 - BioSpace
SDGRSchrodinger, Inc. Latest Stock News & Market Updates - StockTitan
Schrödinger, Inc. Receives an Additional $9.5 Million from the Bill & Melinda Gates Foundation - Marketscreener.com
Schrödinger Awards RSU Grants to New Employees Under Inducement Plan | SDGR Stock News - StockTitan
Biosimulation Market Dynamics and Future Opportunities | 2024 - openPR
Schrödinger Broadens and Accelerates Predictive Toxicology Initiative - BioSpace
Sumitomo Mitsui Trust Group Inc. Increases Stake in Schrödinger, Inc. (NASDAQ:SDGR) - MarketBeat
Leerink Partnrs Decreases Earnings Estimates for Schrödinger - MarketBeat
(SDGR) Technical Data - Stock Traders Daily
Schrodinger Inc (SDGR) Quarterly 10-Q Report - Quartz
Schrodinger (SDGR): Stock Experiences 5% Decline Amid Market Flu - GuruFocus.com
Pier 88 Investment Partners LLC Buys 35,120 Shares of Schrödinger, Inc. (NASDAQ:SDGR) - MarketBeat
Schrödinger Third Quarter 2024 Earnings: EPS Beats Expectations, Revenues Lag - Yahoo Finance
Midtown-based drug company inks $150M deal with Novartis - Crain's New York Business
Rubric Capital Management LP Increases Stake in Schrodinger Inc - GuruFocus.com
Schrödinger, Inc. Provides Earnings Guidance for the Fiscal Year Ending December 31, 2024 - Marketscreener.com
Schrodinger shares target increased, outperform rating on Novartis deal - Investing.com
Flare and Schrödinger join multibillion-dollar collaborations - BioWorld Online
Schrödinger announces collaboration with Novartis - The Pharma Letter
Schrödinger, Inc. (NASDAQ:SDGR) Q3 2024 Earnings Call Transcript - Insider Monkey
Schrodinger announces expanded license agreement with Novartis - Yahoo Finance
Baillie Gifford & Co. Has $36.75 Million Stock Position in Schrödinger, Inc. (NASDAQ:SDGR) - MarketBeat
Market Participants Recognise Schrödinger, Inc.'s (NASDAQ:SDGR) Revenues Pushing Shares 26% Higher - Simply Wall St
Earnings call: Schrödinger reports dip in Q3 revenue, eyes Novartis deal - Investing.com UK
Schrodinger Inc (SDGR) Q3 2024 Earnings Call Highlights: Navigat - GuruFocus.com
Schrodinger Inc (SDGR) Q3 2024 Earnings Call Highlights: Navigating Revenue Challenges and ... By GuruFocus - Investing.com Canada
Schrodinger Inc (SDGR) Q3 2024 Earnings Call Highlights: Navigating Revenue Challenges and ... - Yahoo Finance
Schrödinger Reports Q3 2024 Earnings and New Novartis Collaboration - TipRanks
Schrödinger secures Novartis deal with potential $2.3 billion payout By Investing.com - Investing.com Australia
Schrödinger gains on Novartis deal despite Q3 miss - MSN
Blade Air Mobility Delivers Q3 Earnings Beat And Strong Margins As Restructuring Takes Flight - AOL
Schrodinger Inc (SDGR) Stock Price Up 13.36% on Nov 12 - GuruFocus.com
Schrödinger Scores Big Despite Q3 Miss As Novartis Collaboration Promises Billions In Milestones: Details - Yahoo Finance
Schrödinger surges on Novartis collaboration agreement - ShareCast
Market news - Research the market
Schrödinger, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2024 - Marketscreener.com
Schrödinger secures Novartis deal with potential $2.3 billion payout - Investing.com
Schrödinger enters collaboration pact with Novartis worth up to $2.5 billion - MarketWatch
Schrödinger Reports Third Quarter 2024 Financial Results - Business Wire
Schrodinger Inc Stock (SDGR) Financials Data
Revenue
Net Income
Cash Flow
EPS
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):